Galectin Therapeutics Inc. (Nasdaq: GALT) reported disappointing results for its Phase 2a clinical trial of GR-MD-02 in nonalcoholic steatohepatitis patients with advanced fibrosis sending the stock price plummeting $1.07 to close at $1.40.
Galectin Therapeutics reports disappointing results
September 28, 2016 at 19:07 PM EDT
